NewsBioClin Therapeutics Announces New Leadership to Advance Late-Stage Bladder Cancer Development Program.
Sept 18, 2018BioClin Therapeutics Appoints Scott Myers as Chairman to its Board of Directors.
June 26, 2018BioClin Therapeutics Presents FIERCE-21: Phase 1b/2 Study of Docetaxel + B-701, a Selective Inhibitor of FGFR3, in Relapsed or Refractory Metastatic Urothelial Carcinoma at the American Society of Clinical Oncology (ASCO). Chicago, IL.
June 1, 2018BioClin Therapeutics, Inc. Announces Poster Presentation of B-701 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 17, 2018BioClin Therapeutics featured in May 10th, 2018 article in BioWorld
May 10, 2018BioClin Therapeutics, Inc., Completes $50 Million Series B Financing with Addition of New Investors
May 9, 2018BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer
Jan 9, 2018BioClin Therapeutics Presents New Safety and Efficacy Data on B-701 Program at the 2017 American Society of Clinical Oncology (ASCO)
June 4, 2017BioClin Therapeutics Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital
March 22, 2017BioClin Therapeutics Initiates Phase 2 Clinical Trial Evaluating
B-701 for Treatment of Urothelial Cell Carcinoma
August 10, 2015